CardioGenesis upbeat despite poor sales
This article was originally published in Clinica
Executive Summary
Orthopaedic company Biomet's quarterly profits missed analysts' expectations by one cent. The company is continuing to build its direct sales operations, which has affected its expenses in the quarter. Biomet is building up its Japanese direct sales operations and has also added to its own sales force by the acquisition last November of Synthes-Stratec's reconstructive products division (see Clinica No 983, p 15). In addition, it has added 18 sales representatives to its EBI division. The Warsaw, Indiana-based company had reconstructive product sales of $185 million in the quarter, up 17%, fixation product sales of $54 million, a 2% increase, and spinal product sales of $32 million, up 30%. Sales of the company's "other products" were up 19% to $34 million. The company has authorised the repurchase of $100 million of shares. This is in addition to a similar-sized repurchase plan announced in December 2001. "We continue to believe that our shares represent an excellent investment for the company," said Dane Miller, CEO. "Our continued high levels of earnings have produced cash in excess of our immediate needs and we view this programme as an investment in our future."
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.